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AKT1 and AKT2 isoforms play 
distinct roles during breast cancer 
progression through the regulation 
of specific downstream proteins
Marina Riggio1, María C. Perrone1, María L. Polo1, María J. Rodriguez1, María May1, 
Martín Abba2, Claudia Lanari1 & Virginia Novaro1
The purpose of this study was to elucidate the mechanisms associated with the specific effects of AKT1 
and AKT2 isoforms in breast cancer progression. We modulated the abundance of specific AKT isoforms in 
IBH-6 and T47D human breast cancer cell lines and showed that AKT1 promoted cell proliferation, through 
S6 and cyclin D1 upregulation, but it inhibited cell migration and invasion through β1-integrin and focal 
adhesion kinase (FAK) downregulation. In contrast, AKT2 promoted cell migration and invasion through 
F-actin and vimentin induction. Thus, while overexpression of AKT1 promoted local tumor growth, 
downregulation of AKT1 or overexpression of AKT2 promoted peritumoral invasion and lung metastasis. 
Furthermore, we evaluated The Cancer Genome Atlas (TCGA) dataset for invasive breast carcinomas 
and found that increased AKT2 but not AKT1 mRNA levels correlated with a worse clinical outcome. We 
conclude that AKT isoforms play specific roles in different steps of breast cancer progression, with AKT1 
involved in the local tumor growth and AKT2 involved in the distant tumor dissemination, having AKT2 a 
poorer prognostic value and consequently being a worthwhile target for therapy.
Breast cancer is the most common cancer in women and the second cause of death around the world1. Despite the 
improvement in diagnoses and the advances in tumor therapy, cancer deaths are due to tumor dissemination2. 
Perturbations in normal cell-cell or cell-extracellular matrix interactions lead to a disruption in basement mem-
brane integrity and surrounding tissue invasion, a previous step in metastatic progression3.
PI3K/AKT/mTOR is the most commonly deregulated pathway in the majority of solid tumors including 
breast carcinomas4,5. It has been demonstrated that the overactivation of the pathway contributes to tumorigen-
esis and tumor progression in the mammary gland through growth factor independent cell proliferation6, cell 
invasion7, endocrine receptor deregulation8,9 and resistance to therapy10. It has been demonstrated that PIK3CA, 
AKT and PTEN present increased mutation rates leading to pathway deregulation11. However, the mechanism 
and downstream signals by which PI3K and AKT regulate each step of tumor development and cancer progres-
sion are not completely understood.
In experimental models, PI3KCA mutations have been shown to activate downstream kinase AKT and induce 
oncogenic transformation12,13 hence, these lesions render tumors highly sensitive to PI3K/AKT/mTOR-directed 
therapeutic inhibition. Despite the huge amount of clinical trials targeting the pathway in cancer, the only approved 
drug is Everolimus, an mTOR inhibitor, in combination with Exemestane for advanced hormone receptor positive 
(HR+ )/HER2-negative (HER2− ) breast cancer that progressed on endocrine therapy14,15. However, the relationship 
between pathway activation or PIK3CA mutation and clinical outcome in breast cancer is still controversial16–19.
There are three AKT isoforms; AKT1, AKT2 and AKT3, that share high sequence and structural homology 
but exhibit specific and non-redundant functions in various tumor types6,20–22. In the breast, the role of AKT3 
has been less studied so far, but it seems to have a more preponderant role in triple negative tumors23. Regarding 
AKT1 and AKT2 studies, several transgenic mouse models with mammary carcinomas have been developed, 
and they showed diverse results. In an ErbB2-induced model, Hutchinson et al.24 showed that activation of 
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AKT1 accelerates tumorigenesis but suppresses tumor invasion, whereas Ju et al.25 reported a proliferative and 
pro-migratory role for AKT1. In MMTV-ErbB2/neu and MMTV-PyMTV models, Maroulakou et al.26 reported 
that AKT1 ablation delays tumor formation, but has no effect on metastasis, whereas AKT2 ablation enhances 
mammary tumor growth. Contrarily, in the MTB-IGF-IR model Watson et al.27 reported that AKT1 or AKT2 
ablation delays mammary tumor onset and suppresses tumor growth.
In mouse and human breast cancer cells our group described that the overactivation of AKT1 leads to 
ductal-like tumor growth9 and hormone-independent activation of endocrine receptors8,28. Other studies showed 
that while AKT1 inhibits cell migration by ERK regulation29 or by the degradation of NFAT30, AKT2 promotes 
cell invasion through β 1-integrin31 and palladin upregulation32. These and other studies33,34 have postulated that 
inhibition of AKT1 can lead to enhanced tumor cell invasiveness and metastatic disease. However, none of the 
above mentioned human breast cancer models fully discriminated the specific role for AKT1 and AKT2 on the 
aggressive phenotype and the disease progression in vivo. The present study was designed to analyze the specific 
role and signaling of AKT1 and AKT2 in regulating the different stages of breast cancer progression in two human 
ductal breast cancer cell lines growing in culture and in xenografts.
Results
AKT1, but not AKT2, promotes cell proliferation. It has been shown that the overactivation of AKT1 
leads to increased mammary tumor growth9,20,25,28. In this study, estrogen and progesterone receptor positive 
(ER + /PR + ) IBH-6 and T47D cancer cells were stably modified to upregulate or downregulate specifically AKT1 
or AKT2 isoforms and search for their specific effects on cell proliferation, adhesion and invasion.
The overactivation of AKT1 (myrAKT1) or AKT2 (myrAKT2) was generated with a myristoylation sequence, 
which maintains the constitutively active protein at the cell membrane. Downregulation of AKT1 (shAKT1) or 
AKT2 (shAKT2) was generated with shRNA constructions. The respective modulation of specific isoforms was 
corroborated by the evaluation of protein expression (Fig. 1a and b and Supplementary Fig. S1a, b and c) and 
phosphorylation (Fig. 1c and d and Supplementary Fig. 1d). We could not distinguish isoform-specific regulation 
in the phosphorylation of pSer473AKT (Fig. 1c and d) and pThr308AKT (Supplementary Fig. 1d) what would 
indicate differential activation, because these antibodies do not discriminate between the AKT isoforms.
We then analyzed the effect of AKT modulation on cell proliferation. As expected, in both cell lines, AKT1 
overexpression increased, whereas its downregulation decreased cell proliferation. However, the effect of AKT2 
on cell growth was less clear (Fig. 1e and f). Statistically significant downregulation on cell proliferation was 
only observed in IBH-6 shAKT2 cells (Fig. 1e, right). Furthermore, the inhibition of cell proliferation in IBH-6 
shAKT1 cells was accompanied by cyclin D1 downregulation (Fig. 1g) and by a decrease in S6 expression and 
phosphorylation (Fig. 1h). However, AKT2 had no effect on cyclin D1 or S6 regulation. Similar results were 
observed in T47D cells (Supplementary Fig. 1e and f). These results indicate that in IBH-6 and T47D cells, AKT1, 
but not AKT2, controls cell proliferation through S6 and cyclin D1 regulation.
AKT1 and AKT2 play different roles in cell migration and invasion. We analyzed the effect of spe-
cific AKT downregulation on cell aggressiveness. IBH-6 epithelial cells display a spindle-shaped morphology35. In 
monolayer culture (two dimension, 2D), IBH-6 shAKT1 and IBH-6 shAKT2 cells preserved size and morphology 
compared to IBH-6 shco cells (Supplementary Fig. S2a). T47D shAKT1 and T47D shAKT2 also preserved size 
and morphology in 2D (not shown).
On a three-dimensional (3D) basement membrane Matrigel, IBH-6 shco cells aggregated on top, with 
some cells invading the Matrigel (Supplementary Fig. S2b). Downregulation of AKT1 increased the invasive 
phenotype, while downregulation of AKT2 suppressed this phenotype, and the cells remained as aggregates 
(Supplementary Fig. S2b). Consistently, in a wound-healing assay shAKT1 cells had similar migration capacity 
than IBH-6 shco cells, whereas shAKT2 cells decreased it (Fig. 2a). Furthermore, shAKT1 increased and shAKT2 
reduced the ability to invade the Matrigel (Fig. 2b). The differential effect of AKT1 and AKT2 on the invasive 
phenotype was less evident in T47D cells (not shown).
We then analyzed the effect of dual isoform silencing (shAKT1/2). For this, IBH-6 cells were co-infected to 
simultaneously downregulate AKT1 and AKT2 (Supplementary Fig. S3a). ShAKT1/2 cells decreased prolifera-
tion (Supplementary Fig. S3b), similar to shAKT1 cells. Moreover, the effect of shAKT1 prevailed over the effect 
of shAKT2 and the resultant phenotype was an increase in the migration (Supplementary Fig. S3c) and invasive 
(Supplementary Fig. S3d) capacities of IBH-6 shAKT1/2 cells. These results demonstrate that AKT1 inhibits cell 
migration and invasion per se, and its effect is prevalent over AKT2.
AKT1 and AKT2 opposite regulation of cellular adhesion and invasion proteins. Integrins belong 
to a family of cell membrane receptors involved in cellular-extracellular matrix interactions through protein 
kinases effectors, and in regulating the activity and localization of intracellular and extracellular proteins to favor 
cellular dissemination36,37.
In a previous study, we demonstrated that the overactivation of AKT1 downregulated focal adhesion kinase 
(FAK) expression, leading to a decrease in IBH-6 cell adhesion9. In this study, we analyzed β 1-integrin and FAK 
levels after downregulation of AKT1 or AKT2. β 1-integrin increased in shAKT1 cells (Fig. 2c and d). Consistently, 
phosphorylation of FAK (pFAK) increased in shAKT1 cells and did not change in shAKT2 cells (Fig. 2e and f). 
MMP9 was also increased in shAKT1 cells (not shown). Furthermore, in shAKT1 cells, β 1-integrin and pFAK 
were particularly increased near membrane edges in a punctuated localization (Fig. 2c and e).
We also analyzed the cytoskeleton components F-actin and vimentin, commonly deregulated during cell 
migration. While IBH-6 shAKT1 cells expressed similar levels of F-actin as shco cells, with clearly defined 
actin fibers, IBH-6 shAKT2 cells exhibited a weaker pattern of expression, with non-defined filaments (Fig. 2g). 
Moreover, while IBH-6 shco cells expressed high levels of vimentin, shAKT1 diminished levels of this protein with 
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a polarized pattern (Fig. 2h). ShAKT2 cells also diminished the levels of vimentin, although with a non-polarized 
pattern, consistent with their decreased ability to invade the Matrigel (Fig. 2h). Even though, neither overexpres-
sion of AKT1 nor AKT2 changed cell morphology in 2D (Supplementary Fig. S4a), myrAKT1 cells decreased 
levels and polarization of pFAK (Supplementary Fig. S4b), whereas myrAKT2 cells increased F-actin polymer-
ization (Supplementary Fig. S4c).Wild type (WT) cells presented a similar behavior than ACL-4.1 or pCDNA3 
control transfected cells (not shown). Altogether, these results suggest that cell invasion is regulated differently by 
AKT1 and AKT2 through their downstream effectors. That is, whereas cellular adhesion proteins β 1-integrin and 
FAK are preferentially inhibited by AKT1, the cytoskeleton components F-actin and vimentin are preferentially 
induced by AKT2.
Figure 1. AKT1 promotes cell proliferation in IBH-6 and T47D cell lines. (a and b) WB showing AKT1 
or AKT2 upregulation (left) and downregulation (right) in myrAKT and shAKT cells, respectively. (c, left) 
WB and (d) IF in green showing decreased pSer473AKT levels in AKT1 and AKT2 deficient IBH-6 cells. (c, 
right) WB showing decreased pSer473AKT levels in AKT1 and AKT2 deficient T47D cells. The antibody for 
pSer473AKT recognizes all phosphorylated AKT isoforms in Ser473. (e and f) Cell proliferation in AKT-
overexpressing (left) or -deficient (right) cells. (g) WB (left) and quantification (right) for cyclin D1 in IBH-6 
AKT-deficient cells. (H) IF in green for pSer240S6 (pS6, upper panel) and total S6 (lower panel) in IBH-6 AKT-
deficient cells. Nuclei were counterstained in red with PI. ERK1/2 or α -Tubulin were used as loading controls. 
*p < 0,05; **p < 0,01; ***p < 0,001 vs. control or shco cells. n = 3 (ANOVA, Dunnet’s post-test). Blots in a, b, c 
and g were cropped. Full-length blots are presented in Supplementary Figure S6.
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AKT1 and AKT2 generate different breast cancer phenotypes in xenografts. In a previous work, 
we have shown that IBH-6 myrAKT1 cells injected into immunosuppressed animals generated tumors that grow 
faster than IBH6 ACL-4.1 cells9. Here, we show that IBH-6 shAKT1 cells originated smaller tumors with a lower 
growth rate compared to IBH-6 shco cells (Fig. 3a). On the contrary, IBH-6 shAKT2 cells did not change tumor 
Figure 2. AKT1 and AKT2 play different roles in cell migration and invasion in IBH-6 cells. (a) Wound 
healing assay. Representative pictures at T0 and Tf (21 hours after) of one experiment (left). Bar graphs represent 
the quantification of the migration area (right). (b) Transwell invasion assay (left). Bar graphs indicate the 
average of cells that invaded the Matrigel and attached on the other side of the insert after 26 hours (right). 
(c and e) IF for β 1-integrin and pTyr861FAK (pFAK). (d and f) Representative WB (left) and quantification 
(right) of β 1-integrin and pFAK. (g) IF for phalloidin to stain in red F-actin fibers (left) and quantification 
of F-actin intensity (right). (h) IF for vimentin (left) and quantification of vimentin staining (right). Nuclei 
were counterstained in red with PI (except in g). White arrows show punctuated localization (c and e) and 
actin fibers (g).*p < 0,05; **p < 0,01. n = 3. Blots in d and f were cropped. Full-length blots are presented in 
Supplementary Figure S7.
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latency or growth rate. It is worthwhile to mention that IBH-6 shco cells generated tumors that grow similarly to 
IBH-6 WT cells38 and that all IBH-6-derived cell lines grow in the absence of exogenous hormone supply. Because 
IBH-6 shco and shAKT2 tumors grew so fast, when they reached the maximum permitted size according to NIH 
guidelines and39, the animals were sacrificed, and tumors, lungs and liver were removed to analyze the histology 
and the presence of metastasis.
The tumor histology showed relevant differences depending on the specific AKT isoform downregulated 
(Fig. 3b). IBH-6 shAKT1 tumors were enriched in the spindle fibroblastic-like population, with almost no epithe-
lial cells (Fig. 3b, inset). Furthermore, despite the reduced growth rate, shAKT1 tumors displayed evident signs 
of invasion of the adjacent adipose tissue (Fig. 3b, arrows). Contrarily, IBH-6 shAKT2 tumors displayed a less 
spindle-shaped morphology, with no signs of invasion (Fig. 3b). We analyzed by IHC the expression of AKT1 
and AKT2 in shco and AKT-deficient tumors (Supplementary Fig. S5a and b) to confirm the specific AKT dow-
regulation. ShAKT1 tumors displayed fewer Ki67-positive cells (Fig. 3c) consisting with a reduced proliferation 
rate (Fig. 3a). Finally, the β 1-integrin level in the tumors reproduced the results obtained in cell cultures; that is, 
increased levels in shAKT1 and decreased levels in shAKT2 tumors, compared to shco tumors (Fig. 3d).
At the end of the experiment, 40 days after cell inoculation, no foci of metastasis were found in any of the 
experimental groups (not shown). Nevertheless, the lungs from shAKT1 tumor-bearing animals showed signs 
of inflammation, such as polymorphonuclear cell infiltration (Fig. 3e, left), suggesting a favorable pre-metastatic 
niche for the circulating cells. Long-term experiments (60 days after cell inoculation) with IBH-6 shAKT1 
cells generated lung metastasis (Fig. 3e, right). Long-term experiments were not possible in shco or shAKT2 
tumor-bearing animals because of animal welfare concerns.
Similarly, in T47D xenografts AKT1 silencing reduced tumor growth, whereas AKT2 silencing did not change 
the growth rate compared to control tumors (Fig. 4a). Even though T47D shAKT1 tumors were smaller in size, 
were the only ones with evident signs of invasion, with groups of cells invading the adjacent adipose tissue 
(Fig. 4b, arrows). AKT isoform-specific downregulation was confirmed by IHC (Supplementary Fig. S5c and d). 
T47D shAKT1 tumors expressed low levels of E-cadherin and high levels of vimentin, which could be a prelude of 
a stemness phenotype, whereas shAKT2 tumors showed the opposite pattern, high E-cadherin and low vimentin 
(Fig. 4c). No metastasis foci were observed at the time of sacrifice in any animal with the silenced isoforms (not 
shown).
To confirm the results of the differential invasive function of AKT isoforms, we overexpressed the specific 
isoforms. T47D myrAKT1 xenografts displayed lower tumor latency and increased growth (Fig. 4d), as previously 
observed in IBH-6 myrAKT1 xenografts9. However, after 15 days, the growth rate of T47D myrAKT1 tumors 
was comparable to that of T47D WT tumors (Fig. 4d). This slowdown in the growth rate of T47D myrAKT1 
cells could be because these cells are still dependent on the estradiol supply for growth. T47D myrAKT2 xeno-
grafts displayed similar growth rate as WT xenografts (Fig. 4d), but in fact, they displayed a histology resembling 
lobular tumors with invasion of adjacent muscle tissue (Fig. 4e, arrows). Furthermore, long-term experiments 
(60 days after cell inoculation) showed metastasis foci in the lungs of T47D myrAKT2 tumor-bearing animals 
(Fig. 4f) positive for the epithelial marker cytoqueratin (Fig. 4g). It is worthwhile to mention that T47D WT is 
not a metastatic cell line.
AKT1 and AKT2 tumor levels differentially correlate with the survival in invasive breast carci-
nomas. Finally, to assess whether the AKT1 and AKT2 tumor levels are related to breast cancer progression 
in patients, we evaluated 1105 samples of invasive breast carcinoma available from The Cancer Genome Atlas 
(TCGA) website40,41 consisting of data sets with DNA amplifications, mutations, deletions and mRNA up- and 
downregulations (Fig. 5a). Considering only mRNA expression data profiles for AKT1 and AKT2, we found that 
AKT2 but not AKT1 was associated with lower overall survival (Fig. 5b).
Altogether, our findings from experimental models and the TCGA meta-analysis support the idea that tumor 
progression in breast cancer differentially involves AKT1 and AKT2 isoforms. In conclusion, AKT1 and AKT2 
level might be used as biomarkers of breast cancer progression early in the diagnosis process to discriminate 
which subset of patients could progress sooner and consequently have potentially worse clinical outcomes. We 
provide experimental and clinical evidences that it is mainly AKT2 overexpression that is related to disease pro-
gression and has a worse prognostic value in breast cancer.
Discussion
Our results show that AKT1 and AKT2 isoforms regulate breast cancer cells differently. Here we describe the 
mechanisms by which AKT1 and AKT2 play specific roles in tumor growth and dissemination in IBH-6 and 
T47D human cell lines. We found that AKT1 is relevant for cell proliferation and survival through S6 and cyclin 
D1 upregulation. Both AKT1 and AKT2 are involved in cell migration and invasion, although each isoform dif-
ferentially regulates β 1-integrin, FAK, E-cadherin, F-actin and vimentin expression (Fig. 6a) and consequently 
have opposite effects on the aggressive phenotype (Fig. 6b). AKT1- and AKT2-specific cell functions could be 
appreciated also in vivo transplantation, and we describe invasion of adjacent adipose and muscle tissues as well 
as lung metastasis derived from shAKT1 and myrAKT2 xenografts.
Despite the increasing amount of studies regarding the role of the AKT isoforms in cancer, their specific 
roles are still not clearly elucidated, being the results cell type and context dependent. This highlights the rel-
evance of understanding the specificity of each AKT isoform during cancer progression to better define their 
prognostic value. Most experimental studies to date have made use of hyperactive variants of AKT such as a 
membrane-targeted mutants, or knockdown strategies such as shRNA in vitro. With this approach, the distinct 
roles of AKT1 as a growth inducer and AKT2 as a growth and invasion repressor were well defined in ovarian 
cancer cells, both within the tumor and the microenvironment22. In the breast, most data in transgenic mouse 
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Figure 3. AKT-deficient IBH-6 cells growing as xenografts reproduced in culture differences between 
AKT1 and AKT2 isoforms. (a) Growth curves of IBH-6 shco and AKT-deficient cells in NSG mice. (b) HE 
in tumor samples, arrows indicate tumor invasion of adjacent adipose tissue. IBH-6 shco tumors were poorly 
differentiated, similar to IBH-6 WT carcinomas, with two cell populations clearly defined: one epithelial-like 
and other spindle-shaped (inset). (c) Ki67 and (d) β 1-integrin staining. (e) HE in lungs from IBH-6 shAKT1 
tumor-bearing animals, showing polymorphonuclear cell infiltration (left, indicated by the arrows) and two 
metastasis foci (right) in 6 out of 12 animals. ***p < 0,001. n = 4 in each experimental group for tumor growth 
curves. Experiments were performed by duplicate.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:44244 | DOI: 10.1038/srep44244
models agree that AKT1 is critical for breast cancer induction whereas AKT2 is more involved in the metastatic 
dissemination20,26.
In breast and ovarian cancer cells, AKT2-induced migration and invasion are linked to the upregulation of 
β 1-integrin31, however, in prostate cancer cells, both AKT1 and AKT2 reduced cell migration and invasion 
through downregulating β 1-integrin42. Here we show in IBH-6 cells that the specific downregulation of AKT1, 
but not AKT2, increased β 1-integrin expression and FAK phosphorylation in punctuated membrane areas com-
patible with focal adhesion sites. FAK can be considered up and downstream of AKT in the regulation of growth 
factor and integrin-stimulated cell motility. We have previously shown in the IBH-6 cells that the overactivation 
of AKT1 decreased, whereas the overexpression of PTEN increased FAK levels9. In contrast, in human colon can-
cer cells, Wang et al.43 reported that AKT1, but not AKT2, directly binds to and phosphorylates FAK. Moreover, 
here we showed the involvement of AKT2, but not of AKT1, in the remodeling of the actin cytoskeleton, which is 
also relevant to cancer cell migration. Altogether, our results confirm that AKT2 has a promigratory role in breast 
cancer cells.
Several studies have considered E-cadherin as a tumor suppressor gene, suggesting that its decreased expres-
sion is a requirement for tumor progression. The overexpression of AKT1 in MCF10A cells grown in 3D Matrigel 
and injected into the mouse mammary duct, resemble ductal carcinoma in situ-like lesions44. Similarly, we have 
previously reported that AKT1 is involved in ductal differentiation in 3D cultures and in vivo9 and that myrAKT1 
breast cancer cells form organized and polar-like structures with high E-cadherin expression. Here we show 
that AKT-specific-deficient T47D tumors display the inverse regulation of E-cadherin and vimentin. Despite the 
loss of E-cadherin, AKT1-defficient tumors maintain cohesive invasive cells with higher levels of vimentin. We 
hypothesize that it is most likely the balance between invasive proteins rather than the protein level in individual 
cells, which determines the invasive grade of a tumor. Overall, we speculate that AKT1 functions as an invasion 
suppressor during the early phases of the disease, whereby AKT2 enhances cell invasion and aggressiveness in 
advanced phases of the disease (Fig. 6b).
Figure 4. AKT-expressing T47D xenografts confirm the differential effect of AKT1 and AKT2 on tumor 
growth and invasion. Growth curves of (a) T47D shco and AKT-deficient cells or (d) T47D WT and AKT-
overexpressing cells in NSG mice. (b and e) HE in tumor samples, arrows indicate tumor invasion of adjacent 
adipose or muscle tissue. (c) E-cadherin and vimentin staining in T47D shco and AKT-deficient tumors.  
(f) HE in the lungs of T47D myrAKT2 tumor-bearing animals showing metastasis foci in 8 out of 12 animals. 
(g) IHQ for pan-cytokeratin stains epithelial metastatic cells in the lungs. **p < 0,01; ***p < 0,001. n = 3 in each 
experimental group for tumor growth curves. Experiments were performed by duplicate.
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Finally, we found, in a univariate analysis of 1105 samples of breast invasive cancer from TCGA, that patients 
that carry mutations that increase abundance of AKT1 mRNA level have a better outcome than patients with 
mutations at the level of AKT2, who have shorter overall survival. Consequently, our study proposes that AKT2 
constitutes a prognostic marker of poor clinical outcomes in breast cancer. This conclusion is further supported 
by the cellular mechanisms we described here in two human breast cancer cell lines.
Recent studies that have associated AKT expression with cancer prognosis showed some contradictory results 
depending on the characteristics of the population evaluated and the technical approach45–47. Pereira et al.47 
pointed out that AKT2 is involved in the acquisition of stem cell-like properties, responsible for invasiveness and 
chemoresistance and worst breast cancer outcome. However, Fohlin et al.46 demonstrated that AKT2 and pAKT 
(pSer473AKT) levels were associated with a lower distant recurrence rate. In the same line, Grell et al.45 showed 
that AKT2 expression and concurrent presence of pAKT (pThr308AKT and/or pSer473AKT) linked to better 
outcome in HER2 + metastatic patients treated with Trastuzumab. Moreover, Badve et al.48 found that nuclear 
localization of pAKT (pSer473AKT) was associated with long-term better survival in ER + /PR + breast cancer 
patients. Other studies suggested that AKT1 drives progression in early breast cancer, while AKT2 reverses this 
effect49–51. Furthermore, Plant et al.52 described a shuffle in AKT1 from the nucleus to the cytoplasm during breast 
tumor progression. This event could be also related to differential protein activation in tumor tissue as we report 
here; i.e. proliferation proteins in early stages and ECM remodeling proteins, as β 1-integrin, in advanced stages. 
All these differing evidences advise that a robust assessment of AKT1 and AKT2 in early and late stages of the 
disease is  suggested as new prognostic markers. In prostate cancer patients, AKT expression and phosphorylation 
were significantly associated to unfavorable outcome, with cytosolic AKT1 expression correlated with a higher 
risk of postoperative recurrence53 and pAKT levels predictive of poor clinical outcome4.
Finally, the efforts to dissect the molecular mechanisms of AKT isoform-specific signaling will provide 
new insights for designing more effective and selective therapeutics for cancer treatment23,54–57. In this regard, 
isoform-specific siRNA, microRNAs, inhibitors and antibodies constitute tools to elucidate the relative contribu-
tions of each AKT isoform signal and localization to cancer spreading. Our results in breast cancer cell lines show 
that even though AKT1/AKT2 dual silencing reduces cell proliferation, it surprisingly enhances cell migration 
and invasion. Overall, our results suggest that targeting at the PI3K or AKT1/2 level would not be effective in 
preventing tumor progression, although specifically targeting AKT2-driven signals could be more effective at 
preventing cancer aggressiveness. The challenge now is to try new target therapies directed to AKT2-activated 
downstream signaling in combination with drugs that target PI3K and/or mTOR to achieve optimal efficacy in 
decreasing breast cancer progression. PanAKT inhibitors including MK2206, AZD5363 are currently in clinical 
trials for advanced solid malignancies such as pancreatic, colorectal, breast, and prostate cancers. Selective inhib-
itors for the AKT isoforms have been developed and tested preclinically but have not yet reached clinical trials 
(i.e. CCT128930 with greater selectivity for AKT2 and antitumor activity)58. The effect of these or other AKT 
Figure 5. AKT2 has worse prognosis value than AKT1 in invasive breast carcinomas. (a) AKT1 (alteration 
rate 11%) or AKT2 (alteration rate 10%) genetic alterations in 1105 breast invasive carcinoma samples from 
TCGA. For AKT1 and for AKT2 the predominant alteration in patient samples was upregulation of mRNA.  
(b) Kaplan-Meier curves in the reference population showing that mRNA upregulation of AKT2 was associated 
with worse overall survival (p = 0.0535) than mRNA upregulation of AKT1 (p = 0.935).
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inhibitors in cell aggressiveness deserves further experimental investigation in the light of current data suggesting 
that the AKT isoforms have particular roles. Our study suggests that specific disruption of AKT2 may be prefer-
able to panAKT inhibition for the treatment of advanced breast cancer.
Conclusion
Our findings provide a rationale to guide the use of AKT1 and AKT2 as biomarkers of disease progression and 
potential targets for new therapies. Their use as prognostic indicators highlights the importance of accurately 
assessing the expression of PI3K/AKT/mTOR components if this oncogenic signaling is targeted in the clinical 
setting. Furthermore, the identification of the downstream components of AKT1 and AKT2 signaling involved 
in each step of the disease will facilitate the implementation of new biomarker-driven therapies to delay or block 
progression.
Based on the results shown here, our prediction is that PI3K, panAKT or specific AKT1 inhibition may not 
be recommended, and may even be contraindicated in breast cancer, as it might promote tumor invasiveness and 
cancer dissemination. Contrarily, knockout of AKT2 or its downstream molecules could be a better option to 
improve breast cancer treatment outcomes, at least for metastatic disease.
Materials and Methods
Cell lines and culture. IBH-6 cell line is derived from a 34 years old pre-menopausal woman35, it expresses 
ER and PR and grows in NSG animals without hormone supply38. T47D human cell line requires a previous injec-
tion of 0,25 mg of 17β -estradiol to grow in NSG mice28.
Both cell lines were maintained in DMEM F12 (Sigma Aldrich St. Louis, MO) 10% fetal bovine serum (FBS, 
Natocor Córdoba Argentina) medium. For 3D cultures cells were seeded on Matrigel (BD Biosciences San Jose, CA).
In vitro studies. Transfections and infections. IBH-6 and T47D cell lines were stably transfected to overex-
press AKT1 (pACL4.1-myrAKT19), or AKT2 (pCDNA3-myrAKT2, Addgene #9016). Transfections were per-
formed with Lipofectamine Reagent (Invitrogen) following manufacturer´s instructions. Stable deletion of AKT1 
or AKT2 was performed using specific lentiviral shRNA (TRCN0000022937 for AKT1 or TRCN0000055260 for 
AKT2, Sigma). Shc-002 Non-Target shRNA was used as control vector. For lentiviral preparation specific shRNA 
was cotransfected with pCMV-dR 8.74 packaging plasmid and pMD2.G plasmid into HEK239T cells. After two 
Figure 6. Proposed mechanisms for AKT1 and AKT2 downstream regulation during breast cancer 
progression. (a) Specific signaling of AKT1 and AKT2 and particular downstream protein regulation.  
(b) Representative scheme for AKT1 and AKT2 specific functions on tumor growth and tumor invasion.
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days lentiviral particles were collected and cells were transduced in the presence of Polybrene (Sigma). Cells sta-
bly transfected were selected with 400 μ g/ml Geneticin (G418, Invitrogen) or 5 μ g/ml Puromicin (Calbiochem) 
according to selection gene in each case.
Proliferation assay. 4 × 104 cells were seeded and maintained during 4 days in DMEM F12 5% SFB medium (for 
IBH-6) or 5 days in DMEM F12 2% charcoal stripped FBS (chFBS) + 20 nM insulin (for T47D). The medium was 
changed every other day. At the end of the incubation cells were tripsinized and counted in Neubauer chamber.
Wound healing assay. 5 × 105 cells were seeded 24 hours prior to the experiment. Wound was made with a tip 
and incubated for 21 hours in DMEM F12 5% FBS medium. Photographs were taken all along the wound at the 
beginning (T0) and at the end of the experiment (Tf). Wound healing areas were quantified as T0-Tf using the 
ImageJ software.
Transwell assay. 5 × 104 cells were seeded on top of 8 μ m transwell inserts (BD Biosciences) previously coated 
with 1:6 Matrigel: DMEM F12 medium and incubated for 26 hours. Cells were fixed with cold methanol, stained 
with Cristal Violet 0,1% and the cells that passed through the insert were quantified.
Western blots (WB). Total protein extracts were obtained using RIPA buffer (Sigma). 100 μ g of protein from 
each sample was separated in 10% polyacrylamide electrophoresis gels. Phosphorylated protein’s bands were 
normalized using total proteins, with the density of bands from the control group set arbitrarily to 1.0 using the 
ImageJ software.
Immunofluorescence (IF). Cells were fixed with PFA 4%, blocked with PBS 10% FBS and incubated with 
primary antibodies overnight. After washing with PBS, cells were incubated with FITC or Dylight secondary 
antibodies (Vector Laboratories Burlingame, CA) and nuclei were counterstained with propidium iodide (PI) 
or 4′ ,6-diamino-2-fenilindol (DAPI). Stained cells were analyzed under a Nikon Eclipse E800 Laser Confocal 
Microscope.
PathScan Intracellular Signaling Array Kit. PathScan Intracellular Signaling Array Kit (Chemiluminescent 
Readout) #7323 (Cell Signaling Technology) was performed following manufacturer´s instructions for IBH-6 
and T47D cell lines modified to overexpress or dowregulate AKT isoforms.
In vivo studies. Animals. NOD/LtSz-scid/IL-2Rgamma null mice (NSG) from The Jackson Laboratory 
(Bar Harbor, ME) were bred at IByME Animal Facility and two-month-old virgin females were used for the 
experiments. Animal care and manipulation were performed in agreement with the International Guidelines and 
Regulations from the National Institute of Health. IByME’s Ethical Committee approved the experiments and the 
use of animals for this work CE 023-June 2014.
Xenografts and immunohistochemistry (IHQ). For IBH-6 xenografts, mice were injected subcutaneously with 
5 × 106 cells. For T47D xenografts, mice were implanted subcutaneously with silastic pellets containing 17β -estradiol 
(0.25 mg) and injected subcutaneously with 8 × 106 cells mixed with Matrigel. When tumors were palpable, sizes 
were measured with caliper Vernier and growth curves were performed plotting tumor size (mm2) vs. time.
Tumors, lungs, liver, uterus and ovaries were fixed in 10% formalin, paraffin embedded (FFPE) and sec-
tioned into 5 μ m for histochemical analysis. Tumor and tissue histology were evaluated in hematoxylin/eosin 
(H&E)-stained slides. For IHQ, FFPE tissues were stained for primary antibodies. Primary antiserum was 
detected after incubation with a biotinylated secondary antibody (Vector Laboratories Inc.) using the Vectastain 
Elite ABC Kit (Vector Laboratories Inc.) and the diaminobenzidine (DAB) Chromogen and Substrate Buffer 
(Dako, Agilent Technologies). After IHC, the specimens were counterstained with hematoxylin, dehydrated, and 
mounted.
TCGA analysis. Open data from 1105 breast invasive carcinoma samples from The Cancer Genome Atlas data-
set (TCGA)40,41 and cbioportal platform (http://www.cbioportal.org) were used to link AKT alterations to clinical 
outcomes. For the survival analysis we considered mRNA expression data profiles by RNA Seq for AKT1 and 
AKT2 and an arbitrary overexpression level greater than three standard deviations from the mean in the reference 
population.
Antibodies. Total AKT1/2/3 (8312), phosphorylated Ser473AKT1/2/3 (7985), ERK1/2 (94), β 1-integrin (8978), 
cyclin D1 (753) and actin (1616) were purchased from Santa Cruz Biotechnology; total AKT1 (2938), total 
AKT2 (3063), phosphorylated Ser240/244S6 (2215) and E-cadherin (3195) from Cell Signaling Technology, 
phosphorylated Tyr861FAK (4804) from Abcam, vimentin (V6630) from Sigma, alpha-tubulin (MS-719) from 
Neomarkers and cytokeratin Clones AE1/AE3 (M3515) from Dako.
Statistical analyses. Statistical analyses were performed with the GraphPad Prism™ software 6.0 
(GraphPad, Inc. CA). One way ANOVA followed by Tukey or Dunnet´s post-tests was used to compare means of 
multiple experimental groups. When comparing the means of two different groups, two-sided Student’s t-test was 
applied. Tumor growth curves were studied using regression analysis, and the slopes compared using analysis of 
variance. In all graphs, the mean ± SEM are shown.
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